FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients

Nicola S. Fracchiolla, Silvia Artuso, Agostino Cortelezzi, Anna M. Pelizzari, Paola Tozzi, Maurizio Bonfichi, Federica Bocchio, Livio Gargantini, Elisa De Rosa, Giuseppe D. Vighi, Lucia Prestini, Simona Sammassimo, Niccolò Frungillo, Maria C. Pasquini, Alessandra Ragazzi, Daniele Boghi, Alessia Pastore, Eraldo Lanzi, Giuseppe Gritti, Giulia QuaresminiSimone Voltolini, Roberta Gaiardoni, Consuelo Corti, Maria C. Vilardo, Maria L. La Targia, Giacomo Berini, Massimo Magagnoli, Claudia Bacci, Dario Consonni, Alma L. Rivolta, Giuliana Muti

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Adverse drug reactions (ADRs) reduce patients' quality of life, increase mortality and morbidity, and have a negative economic impact on healthcare systems. Nevertheless, the importance of ADR reporting is often underestimated. The project "FarmaREL" has been developed to monitor and evaluate ADRs in haematological patients and to increase pharmacovigilance culture among haematology specialists. In 13 haematology units, based in Lombardy, Italy, a dedicated specialist with the task of encouraging ADRs reporting and sensitizing healthcare professionals to pharmacovigilance has been assigned. The ADRs occurring in haematological patients were collected electronically and then analysed with multiple logistic regression. Between January 2009 and December 2011, 887 reports were collected. The number of ADRs was higher in older adults (528; 59%), in male (490; 55%), and in non-Hodgkin lymphoma patients (343; 39%). Most reactions were severe (45% required or prolonged hospitalization), but in most cases, they were fully resolved at the time of reporting. According to Schumock and Thornton criteria, a percentage of ADRs as high as 7% was found to be preventable versus 2% according to reporter opinion. Patients' haematological diagnosis, not age or gender, resulted to be the variable that most influenced ADR, in particular severity and outcome. The employment of personnel specifically dedicated to pharmacovigilance is a successful strategy to improve the number and quality of ADR reports. "FarmaREL", the first programme of active pharmacovigilance in oncohaematologic patients, significantly contributed to reach the WHO "Gold Standard" for pharmacovigilance in Lombardy, Italy.

Original languageEnglish
Pages (from-to)299-306
JournalHematological Oncology
Volume36
Issue number1
DOIs
Publication statusPublished - 2018

Fingerprint

Pharmacovigilance
Drug-Related Side Effects and Adverse Reactions
Hematology
Italy
Delivery of Health Care
Non-Hodgkin's Lymphoma
Hospitalization
Logistic Models
Economics
Quality of Life
Morbidity

Keywords

  • Adverse drug reactions
  • Drug safety
  • Medication safety
  • Patient safety
  • Pharmacovigilance

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

FarmaREL : An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients. / Fracchiolla, Nicola S.; Artuso, Silvia; Cortelezzi, Agostino; Pelizzari, Anna M.; Tozzi, Paola; Bonfichi, Maurizio; Bocchio, Federica; Gargantini, Livio; De Rosa, Elisa; Vighi, Giuseppe D.; Prestini, Lucia; Sammassimo, Simona; Frungillo, Niccolò; Pasquini, Maria C.; Ragazzi, Alessandra; Boghi, Daniele; Pastore, Alessia; Lanzi, Eraldo; Gritti, Giuseppe; Quaresmini, Giulia; Voltolini, Simone; Gaiardoni, Roberta; Corti, Consuelo; Vilardo, Maria C.; La Targia, Maria L.; Berini, Giacomo; Magagnoli, Massimo; Bacci, Claudia; Consonni, Dario; Rivolta, Alma L.; Muti, Giuliana.

In: Hematological Oncology, Vol. 36, No. 1, 2018, p. 299-306.

Research output: Contribution to journalArticle

Fracchiolla, NS, Artuso, S, Cortelezzi, A, Pelizzari, AM, Tozzi, P, Bonfichi, M, Bocchio, F, Gargantini, L, De Rosa, E, Vighi, GD, Prestini, L, Sammassimo, S, Frungillo, N, Pasquini, MC, Ragazzi, A, Boghi, D, Pastore, A, Lanzi, E, Gritti, G, Quaresmini, G, Voltolini, S, Gaiardoni, R, Corti, C, Vilardo, MC, La Targia, ML, Berini, G, Magagnoli, M, Bacci, C, Consonni, D, Rivolta, AL & Muti, G 2018, 'FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients', Hematological Oncology, vol. 36, no. 1, pp. 299-306. https://doi.org/10.1002/hon.2451
Fracchiolla, Nicola S. ; Artuso, Silvia ; Cortelezzi, Agostino ; Pelizzari, Anna M. ; Tozzi, Paola ; Bonfichi, Maurizio ; Bocchio, Federica ; Gargantini, Livio ; De Rosa, Elisa ; Vighi, Giuseppe D. ; Prestini, Lucia ; Sammassimo, Simona ; Frungillo, Niccolò ; Pasquini, Maria C. ; Ragazzi, Alessandra ; Boghi, Daniele ; Pastore, Alessia ; Lanzi, Eraldo ; Gritti, Giuseppe ; Quaresmini, Giulia ; Voltolini, Simone ; Gaiardoni, Roberta ; Corti, Consuelo ; Vilardo, Maria C. ; La Targia, Maria L. ; Berini, Giacomo ; Magagnoli, Massimo ; Bacci, Claudia ; Consonni, Dario ; Rivolta, Alma L. ; Muti, Giuliana. / FarmaREL : An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients. In: Hematological Oncology. 2018 ; Vol. 36, No. 1. pp. 299-306.
@article{1274e0bce9cb469d9e6d6c4bb1ff5e49,
title = "FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients",
abstract = "Adverse drug reactions (ADRs) reduce patients' quality of life, increase mortality and morbidity, and have a negative economic impact on healthcare systems. Nevertheless, the importance of ADR reporting is often underestimated. The project {"}FarmaREL{"} has been developed to monitor and evaluate ADRs in haematological patients and to increase pharmacovigilance culture among haematology specialists. In 13 haematology units, based in Lombardy, Italy, a dedicated specialist with the task of encouraging ADRs reporting and sensitizing healthcare professionals to pharmacovigilance has been assigned. The ADRs occurring in haematological patients were collected electronically and then analysed with multiple logistic regression. Between January 2009 and December 2011, 887 reports were collected. The number of ADRs was higher in older adults (528; 59{\%}), in male (490; 55{\%}), and in non-Hodgkin lymphoma patients (343; 39{\%}). Most reactions were severe (45{\%} required or prolonged hospitalization), but in most cases, they were fully resolved at the time of reporting. According to Schumock and Thornton criteria, a percentage of ADRs as high as 7{\%} was found to be preventable versus 2{\%} according to reporter opinion. Patients' haematological diagnosis, not age or gender, resulted to be the variable that most influenced ADR, in particular severity and outcome. The employment of personnel specifically dedicated to pharmacovigilance is a successful strategy to improve the number and quality of ADR reports. {"}FarmaREL{"}, the first programme of active pharmacovigilance in oncohaematologic patients, significantly contributed to reach the WHO {"}Gold Standard{"} for pharmacovigilance in Lombardy, Italy.",
keywords = "Adverse drug reactions, Drug safety, Medication safety, Patient safety, Pharmacovigilance",
author = "Fracchiolla, {Nicola S.} and Silvia Artuso and Agostino Cortelezzi and Pelizzari, {Anna M.} and Paola Tozzi and Maurizio Bonfichi and Federica Bocchio and Livio Gargantini and {De Rosa}, Elisa and Vighi, {Giuseppe D.} and Lucia Prestini and Simona Sammassimo and Niccol{\`o} Frungillo and Pasquini, {Maria C.} and Alessandra Ragazzi and Daniele Boghi and Alessia Pastore and Eraldo Lanzi and Giuseppe Gritti and Giulia Quaresmini and Simone Voltolini and Roberta Gaiardoni and Consuelo Corti and Vilardo, {Maria C.} and {La Targia}, {Maria L.} and Giacomo Berini and Massimo Magagnoli and Claudia Bacci and Dario Consonni and Rivolta, {Alma L.} and Giuliana Muti",
year = "2018",
doi = "10.1002/hon.2451",
language = "English",
volume = "36",
pages = "299--306",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "wiley",
number = "1",

}

TY - JOUR

T1 - FarmaREL

T2 - An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients

AU - Fracchiolla, Nicola S.

AU - Artuso, Silvia

AU - Cortelezzi, Agostino

AU - Pelizzari, Anna M.

AU - Tozzi, Paola

AU - Bonfichi, Maurizio

AU - Bocchio, Federica

AU - Gargantini, Livio

AU - De Rosa, Elisa

AU - Vighi, Giuseppe D.

AU - Prestini, Lucia

AU - Sammassimo, Simona

AU - Frungillo, Niccolò

AU - Pasquini, Maria C.

AU - Ragazzi, Alessandra

AU - Boghi, Daniele

AU - Pastore, Alessia

AU - Lanzi, Eraldo

AU - Gritti, Giuseppe

AU - Quaresmini, Giulia

AU - Voltolini, Simone

AU - Gaiardoni, Roberta

AU - Corti, Consuelo

AU - Vilardo, Maria C.

AU - La Targia, Maria L.

AU - Berini, Giacomo

AU - Magagnoli, Massimo

AU - Bacci, Claudia

AU - Consonni, Dario

AU - Rivolta, Alma L.

AU - Muti, Giuliana

PY - 2018

Y1 - 2018

N2 - Adverse drug reactions (ADRs) reduce patients' quality of life, increase mortality and morbidity, and have a negative economic impact on healthcare systems. Nevertheless, the importance of ADR reporting is often underestimated. The project "FarmaREL" has been developed to monitor and evaluate ADRs in haematological patients and to increase pharmacovigilance culture among haematology specialists. In 13 haematology units, based in Lombardy, Italy, a dedicated specialist with the task of encouraging ADRs reporting and sensitizing healthcare professionals to pharmacovigilance has been assigned. The ADRs occurring in haematological patients were collected electronically and then analysed with multiple logistic regression. Between January 2009 and December 2011, 887 reports were collected. The number of ADRs was higher in older adults (528; 59%), in male (490; 55%), and in non-Hodgkin lymphoma patients (343; 39%). Most reactions were severe (45% required or prolonged hospitalization), but in most cases, they were fully resolved at the time of reporting. According to Schumock and Thornton criteria, a percentage of ADRs as high as 7% was found to be preventable versus 2% according to reporter opinion. Patients' haematological diagnosis, not age or gender, resulted to be the variable that most influenced ADR, in particular severity and outcome. The employment of personnel specifically dedicated to pharmacovigilance is a successful strategy to improve the number and quality of ADR reports. "FarmaREL", the first programme of active pharmacovigilance in oncohaematologic patients, significantly contributed to reach the WHO "Gold Standard" for pharmacovigilance in Lombardy, Italy.

AB - Adverse drug reactions (ADRs) reduce patients' quality of life, increase mortality and morbidity, and have a negative economic impact on healthcare systems. Nevertheless, the importance of ADR reporting is often underestimated. The project "FarmaREL" has been developed to monitor and evaluate ADRs in haematological patients and to increase pharmacovigilance culture among haematology specialists. In 13 haematology units, based in Lombardy, Italy, a dedicated specialist with the task of encouraging ADRs reporting and sensitizing healthcare professionals to pharmacovigilance has been assigned. The ADRs occurring in haematological patients were collected electronically and then analysed with multiple logistic regression. Between January 2009 and December 2011, 887 reports were collected. The number of ADRs was higher in older adults (528; 59%), in male (490; 55%), and in non-Hodgkin lymphoma patients (343; 39%). Most reactions were severe (45% required or prolonged hospitalization), but in most cases, they were fully resolved at the time of reporting. According to Schumock and Thornton criteria, a percentage of ADRs as high as 7% was found to be preventable versus 2% according to reporter opinion. Patients' haematological diagnosis, not age or gender, resulted to be the variable that most influenced ADR, in particular severity and outcome. The employment of personnel specifically dedicated to pharmacovigilance is a successful strategy to improve the number and quality of ADR reports. "FarmaREL", the first programme of active pharmacovigilance in oncohaematologic patients, significantly contributed to reach the WHO "Gold Standard" for pharmacovigilance in Lombardy, Italy.

KW - Adverse drug reactions

KW - Drug safety

KW - Medication safety

KW - Patient safety

KW - Pharmacovigilance

UR - http://www.scopus.com/inward/record.url?scp=85026753787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026753787&partnerID=8YFLogxK

U2 - 10.1002/hon.2451

DO - 10.1002/hon.2451

M3 - Article

AN - SCOPUS:85026753787

VL - 36

SP - 299

EP - 306

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 1

ER -